Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
100 hedge funds and large institutions have $301M invested in Concert Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 9 closing their positions.
1,228% more call options, than puts
Call options by funds: $332K | Put options by funds: $25K
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
50% more capital invested
Capital invested by funds: $201M → $301M (+$101M)
9% more funds holding
Funds holding: 92 → 100 (+8)
10% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 31
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$7.75M |
| 2 |
BlackRock
New York
|
+$4.41M |
| 3 |
M&T Bank
Buffalo,
New York
|
+$4.3M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$3.34M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.2M |
| 2 |
Millennium Management
New York
|
-$1.73M |
| 3 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$706K |
| 4 |
Renaissance Technologies
New York
|
-$577K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$528K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QI
101
QS Investors
New York
| – | -$389K | -39,550 | Closed |
|
|
WG
102
Winton Group
London,
United Kingdom
| – | -$309K | -31,506 | Closed |
|
103
Squarepoint
New York
| – | -$200K | -20,393 | Closed |
|
|
AIM
104
Alambic Investment Management
Belvedere,
California
| – | -$196K | -19,934 | Closed |
|
105
Jane Street
New York
| – | -$163K | -16,647 | Closed |
|
|
ACI
106
AMP Capital Investors
Sydney,
Australia
| – | -$131K | -13,600 | Closed |
|
|
FHA
107
Flagship Harbor Advisors
Boston,
Massachusetts
| – | -$39K | -4,000 | Closed |
|
|
PCM
108
Prelude Capital Management
New York
| – | -$16K | -1,666 | Closed |
|
CNCE Hedge Fund Activity: Q4 2020 in Review
100 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2020, worth a combined $301M — up 50% from $201M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CNCE positions and 9 closed out — a net gain of 8 holders — while 34 added to existing stakes and 31 trimmed.
The largest buyer was Corriente Advisors, opening a new position worth an estimated $7.75M. The largest seller was Alyeska Investment Group, cutting an estimated $2.2M.
- 100 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2020, up from 92 in Q3 2020.
- Funds reported $301M of Concert Pharmaceuticals, Inc. stock for Q4 2020, up 50% quarter-over-quarter.
- 17 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2020 and 9 closed out, a net change of +8 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2020 was Corriente Advisors, an estimated $7.75M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2020 was Alyeska Investment Group, an estimated $2.2M sold.
Based on aggregated 13F filings for Q4 2020.